Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biotime Inc (BTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 346,961
  • Shares Outstanding, K 110,850
  • Annual Sales, $ 5,920 K
  • Annual Income, $ 33,570 K
  • 36-Month Beta 1.92
  • Price/Sales 59.33
  • Price/Cash Flow 0.00
  • Price/Book 2.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.10 +0.97%
on 03/23/17
3.59 -12.81%
on 03/31/17
-0.12 (-3.69%)
since 03/21/17
3-Month
2.70 +15.93%
on 02/10/17
3.62 -13.54%
on 03/17/17
-0.19 (-5.72%)
since 01/20/17
52-Week
2.26 +38.50%
on 06/27/16
4.01 -21.95%
on 09/26/16
-0.01 (-0.32%)
since 04/21/16

Most Recent Stories

More News
BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging

--BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery

BTX : 3.13 (-1.26%)
Regenerative Technology Innovations in the Medical Market

FinancialBuzz.com News Commentary

RP.VN : 0.940 (-5.05%)
REPCF : 0.7070 (-5.28%)
NUVA : 75.02 (-0.90%)
BTX : 3.13 (-1.26%)
AGN : 236.35 (-0.67%)
ATHX : 1.47 (-1.34%)
BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer...

BTX : 3.13 (-1.26%)
BioTime to Present at Oppenheimer 27th Annual Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief...

BTX : 3.13 (-1.26%)
BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for...

BTX : 3.13 (-1.26%)
BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session

BioTime, Inc. (BTX) was above 7% in the last trading session.

BTX : 3.13 (-1.26%)
GLPG : 85.84 (-3.65%)
BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte...

BTX : 3.13 (-1.26%)
BioTime, Inc. Announces Closing of Public Offering of Common Stock

BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its...

BTX : 3.13 (-1.26%)
CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh

Please replace the release dated February 6, 2017, with the following corrected version due to multiple revisions.

BTX : 3.13 (-1.26%)
BioTime to Present at Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief...

BTX : 3.13 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body....

See More

Support & Resistance

2nd Resistance Point 3.20
1st Resistance Point 3.17
Last Price 3.13
1st Support Level 3.11
2nd Support Level 3.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.